| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
126,890,000 |
| Market
Cap: |
1.15(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.79 - $9.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO™ (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
5,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$27,500 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
9,922,851 |
| Total Sell Value |
$0 |
$0 |
$0 |
$60,660,378 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
29 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Craig Adam R |
President and CEO |
• • – |
2022-11-10 |
4 |
AS |
$6.00 |
$1,130,703 |
D/D |
(188,304) |
27,861 |
|
-29% |
|
| Craig Adam R |
President and CEO |
• • – |
2022-11-10 |
4 |
OE |
$0.84 |
$158,382 |
D/D |
188,304 |
216,165 |
|
- |
|
| Craig Adam R |
President and CEO |
• • – |
2022-11-09 |
4 |
AS |
$6.00 |
$324,056 |
D/D |
(53,996) |
27,861 |
|
-24% |
|
| Craig Adam R |
President and CEO |
• • – |
2022-11-09 |
4 |
OE |
$0.84 |
$45,416 |
D/D |
53,996 |
81,857 |
|
- |
|
| Metzger Michael A |
Director |
– • – |
2022-11-08 |
4 |
AS |
$5.53 |
$511,019 |
D/D |
(91,500) |
0 |
|
-26% |
|
| Metzger Michael A |
Director |
– • – |
2022-11-08 |
4 |
OE |
$0.84 |
$86,971 |
D/D |
91,500 |
91,500 |
|
- |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-10-04 |
4 |
AS |
$6.25 |
$13,194 |
D/D |
(2,109) |
16,913 |
|
-12% |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-10-04 |
4 |
OE |
$0.95 |
$2,001 |
D/D |
2,109 |
17,522 |
|
- |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-10-03 |
4 |
AS |
$6.25 |
$1,875 |
D/D |
(300) |
16,913 |
|
-14% |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-10-03 |
4 |
OE |
$0.95 |
$285 |
D/D |
300 |
17,213 |
|
- |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-09-30 |
4 |
AS |
$6.05 |
$845,549 |
D/D |
(139,841) |
16,913 |
|
-10% |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-09-30 |
4 |
OE |
$0.95 |
$132,695 |
D/D |
139,841 |
156,754 |
|
- |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-09-29 |
4 |
AS |
$6.00 |
$5,401 |
D/D |
(900) |
16,913 |
|
-6% |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-09-29 |
4 |
OE |
$0.95 |
$854 |
D/D |
900 |
17,013 |
|
- |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-09-16 |
4 |
AS |
$6.02 |
$136,004 |
D/D |
(22,592) |
16,913 |
|
-5% |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-09-16 |
4 |
OE |
$0.95 |
$21,438 |
D/D |
22,592 |
39,505 |
|
- |
|
| Craig Adam R |
President and CEO |
• • – |
2022-09-12 |
4 |
AS |
$6.43 |
$1,557,989 |
D/D |
(242,300) |
27,861 |
|
-7% |
|
| Craig Adam R |
President and CEO |
• • – |
2022-09-12 |
4 |
OE |
$0.84 |
$203,799 |
D/D |
242,300 |
270,161 |
|
- |
|
| Craig Adam R |
President and CEO |
• • – |
2022-08-16 |
4 |
B |
$5.50 |
$27,500 |
D/D |
5,000 |
27,861 |
2.81 |
2% |
|
| Lampert Mark N |
See Explanation of Responses |
– • • |
2022-08-09 |
4 |
A |
$0.00 |
$0 |
I/I |
1,519,999 |
1,526,147 |
|
- |
|
| Lampert Mark N |
See Explanation of Responses |
– • • |
2022-08-09 |
4 |
S |
$6.12 |
$7,891,336 |
I/I |
(1,289,434) |
6,148 |
|
11% |
|
| Lampert Mark N |
See Explanation of Responses |
– • • |
2022-08-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,863,332 |
702,505 |
|
- |
|
| Lampert Mark N |
See Explanation of Responses |
– • • |
2022-08-09 |
4 |
S |
$6.12 |
$44,128,664 |
D/D |
(7,210,566) |
19,839 |
|
11% |
|
| Metzger Michael A |
Director |
– • – |
2022-07-07 |
4 |
AS |
$6.50 |
$130,995 |
D/D |
(20,121) |
0 |
|
-23% |
|
| Craig Adam R |
President and CEO |
• • – |
2022-07-06 |
4 |
AS |
$6.11 |
$111,343 |
D/D |
(18,223) |
22,861 |
|
-1% |
|
229 Records found
|
|
Page 2 of 10 |
|
|
